PTC Therapeutics announced on November 27, 2024, that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million. The transaction is expected to close upon the satisfaction of customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.
The PRV was granted to PTC Therapeutics on November 13, 2024, in conjunction with the U.S. Food and Drug Administration (FDA) approval of KEBILIDI. KEBILIDI is indicated for the treatment of children and adults with AADC deficiency, covering the full spectrum of disease severity.
The Rare Pediatric Disease Priority Review Voucher program encourages the development of new drugs for rare pediatric diseases. The sale of this voucher provides a significant non-dilutive cash infusion for PTC Therapeutics, enhancing its financial flexibility for future investments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.